The Chairman of the Indian Pharmacopoeia Commission is not merely a titular head but the gatekeeper of a trillion-rupee pharmaceutical ecosystem. To maintain India’s reputation as a reliable drug supplier, the government should:
The Chairman’s ad-hoc committee published 15 new monographs for antivirals (Favipiravir) and biologics (Vaccine excipients) in record time. This demonstrated a shift from a bureaucratic to a crisis-driven leadership model.